tbuckley/cabot-search huggingface dataset:
Catheterization and Roentgen Visualization of the Azygos Vein and Its Tributaries in Laennec's Cirrhosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiology, Pregnancy
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
&lt;TITLE&gt;Neck Injuries&lt;/TITLE&gt;
Journal: JAMA (2001)

Do not move the injured person unless he or she is in danger of further injury.If the person must be moved, get others to help and use a rigid, sturdy support (such as a plank) for moving.Roll the entire body as a unit, moving the head and neck together, onto the surface.Use belts or rope to keep the person's body from moving and hold the surface as horizontally as possible.• Do not bend, twist, or lift the injured person's head, neck, or body.Do not remove a helmet or other protective equipment the person may be wearing.Do not let the person move his or her head, neck, or body.• Check the injured person's breathing and be sure the nose, throat, and mouth are clear.If he or she vomits or is bleeding from the mouth or nose, roll the person on his or her side, keeping the head, neck, and back in a straight line.• Place rolled up towels or clothing on both sides of the person's head and neck to prevent movement.Cover the person for warmth until help arrives.
Continuing Education Opportunities for Physicians September 1992 through February 1993
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hospital charges for laparoscopic and open cholecystectomy
Authors: A. M. Jordan
Journal: JAMA (1991)

<h3>To the Editor.</h3> — I read with interest the Questions and Answers<sup>1</sup>in<i>JAMA</i>and felt compelled to respond to Dr Fitzgibbons' assertion that hospital charges for laparoscopic cholecystectomies are less than charges for open cholecystectomies. As the medical director at Blue Cross/ Blue Shield of South Carolina, I have been interested in the impact that new technology and new procedures have on claims costs. My staff and I have been involved in an ongoing analysis of our claims experience with laparoscopic cholecystectomies. Earlier this year, we compared claims for laparoscopic cholecystectomies performed in 1990 with open cholecystectomies performed in five South Carolina hospitals. We attempted to include only uncomplicated cases in our study and compared hospital charges, surgeon's fees, fees for the assistant at surgery, and the anesthesia professional charges. The results of our study of 22 of our earliest cases (ie, 11 open and 11 laparoscopic cholecystectomies)
Clinical Pharmacology and Toxicology of Dichloroacetate
Authors: Peter W. Stacpoole, George N. Henderson, Zimeng Yan, Margaret O. James
Journal: Environmental Health Perspectives (1998)

Dichloroacetate (DCA) is a xenobiotic of interest to both environmental toxicologists and clinicians.The chemical is a product of water chlorination and of the metabolism of various drugs and industrial chemicals.Its accumulation in groundwater and at certain Superfund sites is considered a potential health hazard.However, concern about DCA toxicity is predicated mainly on data obtained in inbred rodent strains administered DCA at doses thousands of times higher than those to which humans are usually exposed.In these animals, chronic administration of DCA induces hepatotoxicity and neoplasia.Ironically, the DCA doses used in animal toxicology experiments are very similar to those used clinically for the chronic or acute treatment of several acquired or hereditary metabolic or cardiovascular diseases.As a medicinal, DCA is generally well tolerated and stimulates the activity of the mitochondrial pyruvate dehydrogenase enzyme complex, resulting in increased oxidation of glucose and lactate and an amelioration of lactic acidosis.By this mechanism, the drug may also enhance cellular energy metabolism.DCA is dehalogenated in vivo to monochloroacetate and glyoxylate, from which it can be further catabolized to glycolate, glycine, oxalate, and carbon dioxide.It remains to be determined whether important differences in its metabolism and toxicology exist in humans between
Diagnostic Cytopathology for Pathologists, 1986 Postgraduate Institute
Journal: JNCI Journal of the National Cancer Institute (1985)

Diagnostic Cytopathology for Pathologists, 1986 Postgraduate Institute Get access JNCI: Journal of the National Cancer Institute, Volume 75, Issue 2, August 1985, Page 396, https://doi.org/10.1093/jnci/75.2.396-a Published: 01 August 1985
Angiotensin converting enzyme deletion polymorphism does not increase the risk of heart failure
Authors: D.M. McNamara, M.K. Trost, A.D. Palmer, M. Rudy, R.J. Alvarez, W.D. Rosenblum, G.A. MacGowan, S. Murali, A.M. Feldman
Journal: Journal of the American College of Cardiology (1998)
PLAGUE
Authors: Hobart A. Reimann
Journal: JAMA (1941)

<h3>To the Editor:—</h3> We have been repeatedly warned that plague infection is spreading eastward from the Pacific Coast (Eskey, C. R., and Hass, V. H.:<i>Pub. Health Rep.</i><b>54</b>:1467 [Aug. 11] 1939; Hampton, B. C.,<i>ibid.</i><b>55</b>:1143 [June 28] 1940; General Medical News,The Journal, September 13, p. 947). It would seem that more information than exists at present should be at hand before it can be accepted as a fact that the infection is really spreading and before any serious alarm is raised. Infection may indeed seem to be spreading eastward if a research for infected rodents spreads in the same direction. For example, the recent discovery of plague infected rodents in the Dakotas may prompt an extension of investigation eastward into Minnesota and Iowa, and if positive results are obtained in the latter states it would appear that the infection had just arrived there. It would
The Methods of Clinical Diagnosis.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cholera—Worldwide, 1989
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Research priorities for Parkinson's recommended
Authors: C. Marwick
Journal: JAMA (1995)

THE EMPHASIS in research on Parkinson's disease should be put on factors that lead to cell death, the study of genetic susceptibility, improvements in drug therapy, and the identification of clinically useful markers. This was the major advice a broad spectrum of neurologic researchers and clinicians handed to the National Institute of Neurological Disorders and Stroke (NINDS) after a 2-day workshop on research priorities related to Parkinson's disease held in Washington, DC. The workshop was convened at the request of Congress. Initially, said Thomas Chase, MD, chief of the experimental therapeutics branch of the NINDS, Congress wanted the institute to hold a consensus meeting to recommend the best ways to treat the disorder. But, he said, there is not yet enough knowledge to reach a consensus. As an alternative, the NINDS, along with two sister National Institutes of Health (NIH) agencies—the National Institute on Aging, Bethesda, Md, and the National
Neoadjuvant Treatment with Docetaxel Plus Lapatinib (L), Trastuzumab (T), or Both Followed By an Anthracycline Based Chemotherapy in Her2-Positive Breast Cancer: Results of the Randomised Phase Ii Eortc 10054 Study
Authors: H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-Bouvet, K. Zaman, E. Matos, T. Petit, M. Debled, A. Bodmer, P. Vuylsteke, G. Jerusalem, E. Brain, O. Tredan, C.G.M. Messina, L. Slaets, D. Cameron
Journal: Annals of Oncology (2014)
CT scanning of the brain: a revolution in only eight years
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Online Continuing Education Program
Journal: CA A Cancer Journal for Clinicians (2009)

After completing this activity, the learner should be able to:• Define the goals of palliative care and hospice.• Review strategies for estimating the prognosis of patients with advanced cancer.• List strategies for effectively discussing prognostic information with patients to facilitate end-of-life care decisions.The American Cancer Society designates this educational activity for a maximum of one AMA PRA Category 1 Credit™.Physicians should only claim credit commensurate with the extent of their participation in the activity.
'Harm reduction' approach may be middle ground
Authors: P. Cotton
Journal: JAMA (1994)

MEDICINE has been given a back seat in this country's so-called war on drugs. Dealing with drug addiction was once primarily the purview of physicians. But since the initiation of prohibition in the early part of this century, and especially since the "war on drugs" was declared in the 1970s, drug use, abuse, and addiction have been treated primarily as crimes and only secondarily as a public health problem. Critics say this makes the public health problem worse. <h3>Medicine as Cornerstone</h3> Medicine, however, is the cornerstone of an alternative approach to drug policy referred to as "harm reduction." This approach emphasizes comprehensive and compassionate treatment for addiction, with physicians providing medical therapy and not viewing abstinence as the only worthy outcome. International comparison studies suggest that the success of medical treatment for heroin addiction is related to the quality of the treating staff, especially the involvement of physicians, says John
Recent events of special interest to medical education
Authors: C. H. Ruhe
Journal: JAMA (1975)

This section includes information about special studies, reports, legislation, and other events and activities that currently have an influence on, or relation to, medical education and that might be expected to influence the future course of events in medical education. Most of the items listed are extensions of reports given in earlier years and are still in development or in transition. Some of these items are also considered in other sections of the EDUCATION NUMBER. <h3>Coordinating Council on Medical Education</h3> Since it was established late in 1972, after several years of deliberation and discussion, the Coordinating Council on Medical Education (CCME) has progressed rapidly and has become the supervisory body over policy matters at all levels of medical education. The CCME was established by the American Medical Association, American Board of Medical Specialties, American Hospital Association, Association of American Medical Colleges, and Council of Medical Specialty Societies, with representation from
Abstract 17: A Critical Role of TRAF2 in Myocardial Survival and Homeostasis by Suppressing Necroptosis
Authors: Xiaoyun Guo, Haifeng Yin, Lei Li, Yi Chen, Jing Li, Jessica Doan, Rachel Steinmetz, Qinghang Liu
Journal: Circulation Research (2017)

Programed cell death, including apoptosis and necroptosis, is critically involved in ischemic cardiac injury, pathological cardiac remodeling, and heart failure progression. Whereas apoptosis signaling is well established, the regulatory mechanisms of necroptosis and its significance in the pathogenesis of heart failure remain largely unkown. Here we identified TNF receptor-associated factor 2 (Traf2) as a key suppressor of myocardial necroptosis, which critically regulates myocardial survival and homeostasis. It has been shown that transgenic expression of Traf2 protects the heart against ischemia-reperfusion injury, but the underlying mechanisms remain unclear. Moreover, the role of Traf2 in myocardial necroptosis and pathological remodeling has not been investigated in a loss-of-function approach. By generating cardiac-specific Traf2 knockout mice, we found that ablation of Traf2 in the heart induced pathological remodeling and heart failure by promoting necroptotic myocyte death. Importantly, plasma TNFα level was significantly elevated in Traf2 -deficient mice, and genetic ablation of TNFR1 (TNF receptor-1) largely abrogated pathological cardiac remodeling and dysfunction associated with Traf2 deficiency. Mechanistically, our data revealed that Traf2 critically regulates RIP1-RIP3-MLKL necroptosis signaling, with the adaptor protein TRADD (TNFR1-associated death domain protein) as an upstream regulator and TAK1 (TGFβ-activated kinase-1) as a downstream effector. Moreover, Traf2 prevents the degradation of key pro-survival signaling proteins TAK1, FLIP, cIAPs, and NFκB-p65 via the ubiquitin-proteasome pathway. Lastly, genetic deletion of RIP3 largely rescued the cardiac phenotype triggered by Traf2 deletion, further validating a critical role of necroptosis in regulating pathological remodeling and heart failure propensity. Taken together, these results identify an important Traf2-mediated, NFκB-independent, pro-survival pathway in the heart by suppressing necroptosis signaling, which may serve as a new therapeutic target for pathological remodeling and heart failure.
THE PREVENTION OF INDUSTRIAL DISEASE
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stuttering
Authors: G. Andrews
Journal: JAMA (1988)

A RECENT essay<sup>1</sup>and several letters<sup>2,3</sup>inTHE JOURNALdealing with a physician-mother's guilt about her son's stuttering suggested that there continues to be a surprising lack of understanding among some physicians about the nature of stuttering. This is unfortunate, because research findings indicate that there is now substantial empirical information about the nature, development, and management of stuttering. Readers interested in the subject could consult a recent review.<sup>4</sup> <h3>The Syndrome</h3> Developmental stuttering can begin as soon as a child starts speaking in short utterances, but most children begin to stutter between ages 3 and 5. The incidence decreases until puberty, after which the onset of developmental stuttering is rare. Syllable repetitions, especially on the first words of utterances, are the most frequent speech disruptions observed initially. Sound prolongations and tense pauses may also occur. Some children cease stuttering after a few months but in others the
Toxic shock syndrome and the contraceptive sponge
Authors: A. L. Reingold
Journal: JAMA (1986)

A little over five years ago, following the widespread dissemination of the results of epidemiologic studies linking menstrual toxic shock syndrome (TSS) to the use of tampons, many women switched to other forms of menstrual protection. As a result, the percentage of menstruating women who used tampons fell from 70% to 49%. In addition, the manufacturer of a single brand of tampons withdrew its product from the market after further studies demonstrated that users of that brand were at increased risk of developing menstrual TSS compared with users of other brands. In these studies, the relative risks or odds ratios (the extent to which users of a given product were at increased risk of developing TSS, compared with nonusers) were in the range of 8 to 30. Thus, tampon users in general were approximately 18 times as likely to develop menstrual TSS as nonusers,<sup>1</sup>and users of Rely brand